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Background: The present study examines a hypothesis that 
short allergen-derived peptides may shift an Aspergillus fu-
migatus (Afu-) specific TH2 response towards a protective 
TH1. Five overlapping peptides (P1-P5) derived from Asp f1, 
a major allergen/antigen of Afu, were evaluated for prophy-
lactic or therapeutic efficacy in BALB/c mice. Methods: To 
evaluate the prophylactic efficacy, peptides were intranasally 
administered to naïve mice and challenged with Afu-aller-
gens/antigens. For evaluation of therapeutic efficacy, the 
mice were sensitized with Afu-allergens/antigens followed 
by intranasal administration of peptides. The groups were 
compared for the levels of Afu-specific antibodies in sera and 
splenic cytokines evaluated by ELISA. Eosinophil peroxidase 
activity was examined in the lung cell suspensions and lung 
inflammation was assessed by histopathogy. Results: 
Peptides P1-, P2- and P3 decreased Afu-specific IgE (84.5∼ 
98.9%) and IgG antibodies (45.7∼71.6%) in comparison with 
Afu-sensitized mice prophylactically. P1- and P2-treated 
ABPA mice showed decline in Afu-specific IgE (76.4∼88%) 
and IgG antibodies (15∼54%). Increased IgG2a/IgG1 and 
IFN-γ/IL-4 ratios were observed. P1-P3 prophylactically 
and P1 therapeutically decreased IL-5 levels and eosinophil 
peroxidase activity. P1 decreased inflammatory cells’ infiltra-
tion in lung tissue comparable to non-challenged control. 
Conclusion: Asp f1-derived peptide P1, prophylactically and 
therapeutically administered to Balb/c mice, is effective in 
regulating allergic response to allergens/antigens of Afu, 
and may be explored for immunotherapy of allergic aspergil-
losis in humans.
[Immune Network 2009;9(5):179-191]
INTRODUCTION
Allergic  bronchopulmonary  aspergillosis  (ABPA),  an  allergic 
disorder induced by the fungal pathogen Aspergillus fumiga-
tus (Afu), is characterized by the presence of both type I and 
type  III  mediated  hypersensitivity  reactions  leading  to  in-
creased levels of total IgE, specific IgE (Afu-IgE), specific IgG 
(Afu-IgG), blood and pulmonary eosinophilia and upregula-
t i o n  o f  T H 2  p a t h w a y  w i t h  t h e  s e c r e t i o n  o f  I L - 4 ,  I L - 5 ,  I L - 6 ,  
IL-10 and IL-13 cytokines (1). Increased incidences of ABPA 
in patients of cystic fibrosis (1∼15%), asthma (1∼11%) and 
Aspergillus skin test-positive asthmatic subjects (24∼28%) de-
mand  therapeutics  that  can  potentially  inhibit  pathological 
conditions induced by Afu (2-4). Importance of TH2 cytokine 
biology  in  propagating  inflammatory  and  pathological  re-
sponses  in  ABPA,  suggest  that  inhibition  of  TH2  response 
could provide promising therapy against ABPA. It is well es-
tablished  that  TH1  cells  produce  cytokines  which  down-
regulate TH2-induced allergic responses (5). In view of the 
above  fact,  restoring  TH1/TH2  balance  by  inducing  aller-
gen-specific TH1 responses has been found to be a promising 
approach in allergen-specific immunotherapy (SIT). SIT shifts 
the balance of T-cell subsets from TH2- to TH1-type to pro-
duce  a  long-term,  antigen-specific,  protective  immune  re-
sponse with an increase in allergen-specific  “blocking” IgG 
and  induction  of  IL-10  secreting  T-regulatory  or  suppressor 
cells (5-11). However, use of allergen-SIT has been cautioned 
in fungal allergic diseases as type III reactions are contributors 
to pathogenesis rather than protection. There are no reports Asp f1 Epitopes Protective Against Allergic Aspergillosis
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Figure 1. Schematic representation of immunization/treatment schedule followed for prophylactic (A) and therapeutic (B) regimens with Asp f1
peptides P1-P3. i.n.: Intranasally, i.p.: Intraperitoneally, CFA: Complete Freund’s adjuvant, IFA: Incomplete Freund’s adjuvant, 3wcf: three-week 
culture filtrate. 
for allergen-SIT for ABPA but has been reported for asthma 
induced by Cladosporium herbarum and Alternaria alternata 
using purified allergen extracts (12-14). Due to risks involved 
with whole allergen-immunotherapy and benefits of a stand-
ardized manufacture of peptides, attention has been focused 
to  immunotherapy  with  peptides  that  display  reduced  IgE- 
binding  while  retaining  T-cell  epitopes.  It  is  now  plausible 
to  attempt  the  peptide-specific  therapy  against  Afu-induced 
allergic  diseases  owing  to  availability  of  annotated  genome 
sequence of Afu and knowledge of characterized immunodo-
minant  allergens/antigens.  Relevant  epitopes  in  these  aller-
gens/antigens have been identified both by prediction algo-
rithms  and  by  experiment  (15-22).
    One of the earliest known and characterized allergen/anti-
gen of Afu is Asp f1 with 85% of allergic aspergillosis patients 
showing IgE antibodies to Asp f1 (17,18,23-25). Asp f1 is a 
cytotoxic  ribonuclease  hindering  its  use  for  immunotherapy 
i n  a  n a t i v e  f o r m  o w i n g  t o  t h e  p o s s i b l e  t o x i c i t i e s  a n d  
IgE-mediated side effects. The present study was undertaken 
to  identify  promising  Asp  f1  peptide  candidates  with  capa-
bility of programming the functional activity of Asp f1-specific 
T  cells  to  TH1  type.  Studies  by  various  groups  suggested 
presence of T cell epitopes in the N-terminal region of Asp 
f1  (1  to  20  amino  acid  residues)  (15,16,26).  In  an  earlier 
study, we evaluated five overlapping peptides (P1-P5) from 
the N-terminal region of Asp f1 for diagnostic relevance (19). 
The same peptides in the present study were predicted for 
t h e i r  b i n d i n g  t o  M H C  c l a s s  I I  a l l e l e s  o f  B A L B / c  m i c e ,  a n d  
evaluated for induced cytokine profile in splenocytes of Afu 
sensitized mice (referred as ABPA mice). Three of these pep-
tides (P1-P3) with significant stimulation index were prophy-
lactically  administered  to  naïve  mice,  and  mice  were  eval-Asp f1 Epitopes Protective Against Allergic Aspergillosis
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Table I. Sequences of peptides P1-P5 derived from the N-terminal
region of Asp f1
Peptides Sequence (amino acids)
P1 LNPKTNKWEDK (10∼20)
P2 INQQLNPK (6∼14)
P3 INQQLNPKTNKWEDK (6∼20)
P4 TNKWEDK (14∼20)
P5 LNPKTNKWEDKRY (10∼22)
uated for protection against challenge with Afu allergens/anti-
gens  (Fig.  1).  Studies  were  also  conducted  to  investigate 
whether these peptides can therapeutically downregulate es-
tablished TH2 responses in murine model of pulmonary fun-
gal  hypersensitivity  caused  by  Afu  (which  mimic  immuno-
logical  profile  of  ABPA).
MATERIALS AND METHODS
In silico prediction of binding affinity of peptides (P1- 
P5) with human and mouse MHC class II molecules
As reported earlier, five overlapping synthetic peptides P1-P5 
from the N-terminal region of  Asp  f1  were  observed  to  be 
immunodominant (19). Binding affinity (IC50) of these pep-
tides to major human HLA-DR molecules was predicted using 
Support  Vector  Machine  (SVM)  method  (27).  The  binding 
with BALB/c MHC class II molecules i.e., I-A
d and I-E
d was 
predicted  by  the  available  online  server,  PRED
BALB/C ( 2 8 ) .
  For SVM prediction method, the dataset of peptides with 
pre-determined  IC50 v a l u e s  w i t h  H L A - D R 2 ,  D R 4 ,  D R 5 ,  D R 7  
and preponderant alleles like DRB1*1501 (DR2) and DRB1* 
0401  (DR4)  were  collected  from  AntiJen  database  (http:// 
www.jenner.ac.uk/antijen/)  and  MHCBN  database  (http:// 
www.imtech.res.in/raghava/mhcbn). This dataset containing 
the  peptides  and  their  binding  affinity  (experimentally  de-
termined)  was  used  as  an  input  for  the  Support  Vector 
Machine. SVM parameters were optimized in order to devel-
op  the  best  model  and  the  method  was  validated  using 
five-folds cross validation and leave one out cross validation. 
Correlation between the actual and the predicted affinity val-
ues  was calculated  and  the model  at  which the  correlation 
was the highest (＞0.5) was selected as the SVM model for 
prediction  of  binding  affinities  of  peptides  P1-P5  (27,29). 
Peptides  were  arbitrarily  classified  based  on  their  predicted 
IC50 values (high-affinity binders: IC50≤500 nM, medium-af-
finity binders: 500 nM＜IC50≤1,500 nM, low-affinity binders: 
1,500＜IC50≤5,000  nM  and  non-binders:  5,000＜IC50).
Peptide synthesis and purification
As  reported  earlier,  peptides  P1-P5  were  synthesized  using 
solid  phase  methodology  by  standard  Fmoc-chemistry  and 
purified by reverse-phase HPLC on an analytical CE-18 col-
umn (Applied BioSystems) and characterized by FAB-MS (Fast 
atom bombardment mass spectrophotometry) (Jeol JMS-360) 
(19). Amino acid sequences of the peptides are given in the 
Table  I.
Allergens/Antigens
Three-week  culture  filtrate  allergens/antigens  (3wcf;  protein 
enriched antigenic fraction) of Afu (clinical strain 285, isolated 
from the sputum of an ABPA patient visiting the V. P. Chest 
Institute,  Delhi,  India)  used  for  the  following  experiments 
were prepared as described earlier (19,30). The three-week 
culture filtrate was observed to be enriched with diagnosti-
cally relevant allergens including Asp f1 as reported by our 
group and others (18,23). The suitability of the antigen was 
determined by its immunoreactivity with specific IgG and IgE 
a n t i b o d i e s  i n  s e r a  o f  c l i n i c a l l y  c o n f i r m e d  A B P A  p a t i e n t s  b y 
ELISA  and  Western  blotting  techniques.
Mice
Specific-pathogen-free, 6∼8 week old BALB/c mice were ob-
tained  from  the  National  Institute  of  Nutrition,  Hyderabad, 
India.  They  received  Purina  chow  and  acidified  water  ad 
libitum.  Mice  were  randomized  before  experiments  were 
performed.  All  procedures  involving  the  handling  of  mice 
were  approved  by  the  institute’s  animal  ethics  committee.
Sensitization of BALB/c mice with 3wcf
A murine model of pulmonary hypersensitivity was prepared 
as described previously (30) and called “ABPA mice” for de-
scriptive  convenience.
Lymphoproliferation assay with Asp f1 peptides using 
ABPA mice splenocytes
To  assess  whether  Asp  f1  peptides  (P1-P5)  can  stimulate 
Afu-sensitized splenocytes of ABPA mice, in vitro splenocytes 
proliferation was carried out as described previously (19,34).   
Briefly, mice were sacrificed and spleens were removed asep-
tically  and  placed  in  an  ice-cold  PBS.  After  gentle  dis-
sociation, cellular suspensions were cultured in a volume of 
100 μl in 96-well flat-bottom plates at the density of 2×10
5 
cells.  Peptides  and  3wcf  (final  concentration  −5  μg/ml) Asp f1 Epitopes Protective Against Allergic Aspergillosis
Neelkamal Chaudhary, et al.
182 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 5 October 2009
were  added  into  the  culture  medium  and  allowed  to  pro-
liferate in RPMI-1640 medium with 10% (v/v) fetal calf serum 
and  10  μg/ml  gentamicin  at  37
oC  and  5%  CO2  for  72  hr. 
10 μl of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide] (Sigma Aldrich, Delhi, India) (5 mg/ml) was 
put in wells, kept for 2∼3 hr; cells were lysed with 0.04 N 
isopropanol-HCl  and  read  at  572  nm.
    Stimulation  Index  was  obtained  as:  OD572  nm v a l u e  a f t e r  
stimulation  with  3wcf  or  peptides/  OD572  nm v a l u e  w i t h o u t  
stimulation.
Treatment of naïve and ABPA mice with peptides 
P1-P5
The  immunization/treatment  schedule  followed  for  prophy-
lactic  and  therapeutic  regimens  was  optimized  considering 
previous studies (31,32). Schematic details of the schedule are 
outlined in Fig. 1. The mice were divided into five groups 
for  each  regimen  (prophylactic  and  therapeutic),  with  five 
mice in each group: Non-challenged control mice, P1-treated 
mice, P2-treated mice, P3-treated mice and PBS-treated ABPA 
or  Afu c h a l l e n g e d  m i c e .
Cytokines in supernatants of spleen cultures before 
and after treatment
Splenocytes of various groups of mice i.e., peptide-treated, 
PBS-treated and control mice after both prophylactic and ther-
apeutic regimens, were allowed to proliferate as described in 
previous section. Peptides and 3wcf (final concentration −5 
μg/ml)  were  added  into  the  culture  medium  and  allowed 
to  proliferate  in  RPMI-1640  medium  (Sigma  Aldrich,  Delhi, 
India) with 10% (v/v) fetal calf serum (Biological Industries, 
Israel) and 10 μg/ml gentamicin at 37
oC and 5% CO2 for 72 
hr. Splenic supernatants obtained were assayed for IL-4, IFN-
γ and IL-5 levels according to the manufacturer’s instructions 
( B D  O p t E I A  k i t s ,  B D  P h a r m i n g e n ,  C A ,  U S A ) .
Detection of Afu-specific IgE and IgG antibodies
The Afu-IgG and Afu-IgE levels in the serum were measured 
by  ELISA,  as  reported previously (33). The serum dilutions 
used for IgG and IgE estimation were 1：100 (v/v) and 1：10 
(v/v),  respectively.  Horseradish  peroxidase  labeled-goat  an-
ti-mouse  IgG  (Sigma  Aldrich,  Delhi,  India)  and  IgE  (Bethyl 
Labs,  TX,  USA)  conjugates  were  used  at  1：1,000  (v/v) 
dilutions. The optical densities at 490 nm were measured with 
an  ELISA  reader  (SpectraMAX  190,  Molecular  Devices,  CA, 
USA).
IgG isotype specific ELISA
The Afu-IgG1 and IgG2a responses were measured by ELISA 
as described earlier (33). The serum dilution used for IgG1 
and IgG2a estimation was 1：100 (v/v). Horseradish perox-
idase-labeled rat anti-mouse IgG1 and IgG2a (BD pharmin-
gen, CA, USA) antibodies were used at 1：1,000 (v/v) dilu-
tions. The optical densities at 490 nm were measured with 
an  ELISA  reader  (SpectraMAX  190,  Molecular  Devices,  CA, 
USA).
Eosinophil peroxidase (EPO) assay
EPO assay, an indicator of number of eosinophils in activated 
state, was performed as described earlier (30). Briefly, lung 
cell suspension (200 μl/well) was plated in a 96-well tissue 
culture plate and incubated in a humidified CO2 incubator at 
37
oC for 48 hours. The medium was aspirated and o-phenyl-
ene  diamine  (OPD)  was  added  (100  μl  of  1  mM  solution 
was prepared using sterile PBS containing 0.1% vol/vol Triton 
X-100 and 0.0125% vol/vol H2O2). After 30-minute incubation 
at  room  temperature,  the  color  reaction  was  terminated  by 
addition of 50 μl of 4 N H 2SO4, and the A492 was measured.
Histological examination of the lung sections
Lungs removed from the sacrificed mice were trimmed of ex-
traneous tissue and fixed in 10% (v/v) formaldehyde and stor-
ed at 4
oC. The tissue sections, made using a microtome and 
stained with hematoxylin and eosin, were examined at x20.
Statistical analysis
Unless  stated  otherwise,  all  d a t a  a r e  e x p r e s s e d  a s  m e a n ±  
standard deviation (SD), with five mice per group. Differen-
ces between the mean values of untreated and treated groups 
were analyzed using student’s unpaired t-test available at the 
site  http://home.clara.net/sisa/t-test/htm.  A  p-value  ＜0.05 
was considered statistically significant. The data reported was 
pooled from three independent experiments, unless specified 
otherwise.
RESULTS
In silico prediction for binding affinities of Asp f1 
peptides with MHC class II alleles
Peptides P1-P5 were observed to be predicted binders using 
PRED
BALB/c server to MHC class II alleles, IA
d and IE
d (data 
not shown). Peptides P1-P5 exhibited medium binding affin-
ity  (500  nM＜IC50≤1,500  nM)  to  multiple  HLA-DR  alleles Asp f1 Epitopes Protective Against Allergic Aspergillosis
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Table II. Predicted binding affinities (IC50) of Asp f1 peptides P1-P5 for dominant HLA-DR molecules
a
Peptides DR2 DR4 DR5 DR7 DRB1*1501 DRB1*0401
P1 473.50 418.52   89.86 1,063.55 1,705.41 1,362.89
P2 459.57 476.21 954.72 1,112.92    718.89    592.10
P3 458.42 389.57 266.06 1,101.09 1,176.40    759.60
P4 443.67 563.45 449.24 1,034.03 1,051.35 1,312.27
P5 503.24 323.90 168.93 1,260.13 1,901.76    814.72
aIC50 values are expressed in nM and have been predicted following Support Vector Machine method as described in Materials and 
methods. Peptides showing the predicted IC50 values inferior to 5,000 nM are considered to be predicted binders in this method
Figure 2. Afu-specific IgE and IgG antibody levels in sera after 10
th day of prophylactic (A) and therapeutic (B) treatment with PBS or Asp f1
peptides P1-P3. Each regimen had 5 groups of mice: Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), 
P1-treated, P2-treated and P3-treated mice. Data represents O.D. at 492 nm and error bars indicate the mean±SD of triplicate determinations 
with five mice per group, *p＜0.05 versus PBS-treated ABPA/Afu challenged mice.
s u c h  a s  H L A - D R 2 ,  H L A - D R 4 ,  H L A - D R 5 ,  H L A - D R 7  a n d  a l s o  
with preponderant alleles such as HLADRB1*1501 (DR2) and 
HLADRB1*0401 (DR4) following SVM method except P1 and 
P5 which showed low binding to DRB1*1501 (Table II). With 
alleles DR2, DR4 and DR5, binding affinities were predicted 
to  be  higher  for  peptides  P1  and  P3.  Peptides  P2  showed 
higher binding to DR2 and DR4 allele while P5 peptide with 
alleles DR4 and DR5. Peptide P1 showed the highest binding 
(IC50∼90 nM) with DR5 allele. Peptide P2 also showed high-
er binding to preponderant alleles DRB1*1501 and DRB1*0401 
when  compared  to  other p e p t i d e s  ( T a b l e  I I ) .
Asp f1 peptides induce proliferation of ABPA mice 
splenocytes
ABPA mice splenocytes were challenged in vitro with 3wcf 
and peptides P1-P5 (5 μg/ml) and were analyzed for their 
stimulation index. Peptides P1-P3 showed higher stimulation 
index (up to 2.4-fold) indicating that they are Asp f1-derived 
immunodominant  epitopic  regions  recognized  by  Afu-sensi-
tized  splenocytes  (data  not  shown).  Peptides,  P1-P3  were 
therefore  selected  for  further  evaluation  in  BALB/c  mice.
Downregulation of Afu (3wcf)-specific antibody le-
vels by Asp f1 peptides
A significant increase in Afu-IgE and Afu-IgG levels was ob-
served in the groups of ABPA mice before any treatment and   
in Afu-challenged mice immunized for two weeks with 3wcf 
(without  any  prior  treatment),  in  comparison  with  those  of 
non-challenged  control mice  immunized  with PBS alone (p
＜0.05)  (Fig.  2).Asp f1 Epitopes Protective Against Allergic Aspergillosis
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Figure 3. Afu-specific IgG2a and IgG1 antibody levels in sera of PBS-treated and peptide-treated mice groups (P1-P3) after 10
th day of  prophylactic
(A) and therapeutic (B) regimen quantitated by indirect ELISA and their respective IgG2a/IgG1 ratios shown below the graph. Each regimen had 
5 groups of mice: Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), P1-treated, P2-treated and P3-treated
mice. Data represents the mean±SD of triplicate determinations with five mice per group, *p＜0.05 versus PBS-treated Afu challenged 
(prophylactic) or ABPA mice (therapeutic).
    In prophylactic regimen, P1-, P2- and P3-treated naïve mice 
showed significant suppression in Afu-specific IgE levels i.e., 
98.9%, 94% and 84.5%, respectively on day 36 (Fig. 2A, p
＜0.05)  in  comparison  to  PBS-treated  Afu-challenged  mice. 
Similarly,  when  compared  to  PBS-treated  Afu-challenged 
mice,  there  was  significant  suppression  in  Afu-specific  IgG 
levels  up  to  71.6%,  69.4%  an d  4 5 . 7 %  i n  P 1 - ,  P 2 -  a n d  
P3-treated mice, respectively after two-week challenge of Afu 
a l l e r g e n  ( F i g .  2 A ,  p ＜0.05).
    When compared to PBS-treated ABPA mice, therapeutic ad-
ministration of peptides P1 and P2 for 3 consecutive days re-
sulted in decrease of  Afu-IgE  levels  up  to  76.4%  and  88%, 
respectively  on  day  42  of  the  study  (Fig.  2B,  p＜0.05). 
However, P3-treated ABPA mice did not show significant de-
crease  (∼12.7%)  in  specific  IgE  levels  (Fig.  2B,  p＞0.05).
    In  comparison  to  PBS-treated  ABPA  mice,  P1-  and  P3- 
treated  ABPA  mice  showed  53.6%  and  39.8%  decrease  in 
Afu-specific  IgG  levels  following  therapeutic  regimen,  re-
s p e c t i v e l y  ( F i g .  2 B ,  p ＜0.05).  No  significant  decrease  in 
Afu-specific IgG levels was observed in P2-treated ABPA mice 
following  therapeutic  regimen  (Fig.  2B,  p＞0.05).
    P1-, P2- and P3-treated naïve mice in a prophylactic regi-
men showed decreased Afu-IgG1 levels while specific IgG2a 
levels remained unaltered after challenged to Afu allergens for 
two weeks (Fig. 3A, p＜0.05). The IgG2a/IgG1 ratios were 
4-fold,  13.4-fold  and  9.4-fold  higher  than  PBS-treated  Afu- 
challenged mice in P1-, P2- and P3-treated mice, respectively. 
In therapeutic approach, IgG2a/IgG1 ratios were 3-fold and 
7.15-fold  higher  than  PBS-treated  ABPA  mice  in  P1-  and 
P2-treated  ABPA  mice,  respectively  (Fig.  3B,  p＜0.05).  P3- 
treated ABPA mice showed unaltered levels of specific IgG1 
antibodies with decreased IgG2a levels thus lowering the ratio 
of IgG2a/IgG1 in comparison to PBS-treated ABPA mice (Fig. 
3B,  p＞0.05).
Asp f1 peptides induce higher IFN-γ/IL-4 ratios
Ratios of IFN-γ/IL-4 in splenic supernatants of PBS-treated 
Afu-challenged and ABPA mice were found to be 1.98±0.049 
and  1.38±0.069,  respectively  (Fig.  4A).
    In prophylactic regimen, P1-, P2 and P3-treated naïve mice Asp f1 Epitopes Protective Against Allergic Aspergillosis
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Figure 4. Levels of IFN-γ and IL-4 cytokines in splenic supernatants of PBS/peptide-treated mice groups (P1-P3) in prophylactic (A) and therapeutic 
regimen (B) quantitated by sandwich ELISA and their respective IFN-γ/IL-4 ratios shown below the graph. Each regimen had 5 groups of mice:
Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), P1-treated, P2-treated and P3-treated mice. Data 
represents the mean±SD of triplicate determinations with five mice per group, *p＜0.05 versus PBS-treated Afu challenged (prophylactic) or
ABPA mice (therapeutic).
showed 9.74-fold, 12.4-fold and 3.8-fold higher IFN-γ/IL-4 
ratios,  when  compared  to  PBS-treated  Afu-challenged  mice 
(Fig. 4A, p＜0.05). While in a therapeutic regimen, P1-, P2- 
and P3-treated mice showed 9.2-fold, 16.2-fold and 1.9-fold 
higher  IFN-γ/IL-4  ratios,  when  compared  to  PBS-treated 
ABPA  mice  (Fig.  4B,  p＜0.05).
Asp f1 epitopes reduce lung EPO activity, IL-5 levels 
and lung eosinophilia
In prophylactic regimen, P1-, P2- and P3-treated naïve mice 
showed marked reduction of 25%, 47.2% and 46.2% in lung 
EPO  activity,  respectively  in  comparison  to  PBS-treated 
Afu-challenged  mice  (Fig.  5A,  p＜0.05).  Therapeutic  ap-
proach, when compared to PBS-treated ABPA mice, P1-trea-
ted ABPA mice showed up to 30.8% decrease in lung eosino-
p h i l i c  i n d e x  ( E P O )  ( F i g .  5 A ,  p ＜0.05).  P2-  and  P3-treated 
ABPA mice showed unaltered levels of lung EPO index (Fig. 
5A,  p＞0.05).
    The reduction in the lung EPO activity correlated well with 
the concomitant reduction in the IL-5 production (Fig. 5B). 
Following  the  prophylactic  regimen,  when  compared  with 
PBS-treated Afu-challenged mice, levels of IL-5 cytokine were 
found to be significantly inhibited in P1 (37.7%), P2 (71.6%) 
and  P3  (61.9%)-treated  naïve  mice  (Fig.  5B,  p＜0.05).  In 
therapeutic regimen, IL-5 levels were significantly decreased 
in P1-treated ABPA mice (up to 26.5%) (Fig. 5B, p＜0.05). 
P2-  and  P3-treated  ABPA  mice  showed  unaltered  levels  of 
I L - 5  c y t o k i n e  ( F i g .  5 B ,  p ＞0.05).
    As shown in Fig. 6, histopathological examination of lung 
sections of Afu-challenged and ABPA mice treated with PBS 
alone revealed the extensive chronic inflammatory infiltrates, 
mainly  representing  lymphocytes  and  eosinophils  (Fig.  6A, 
B). These inflammatory cells were frequently located around 
perivascular and peribronchiolar areas. Mice in the PBS-treat-
ed  non-challenged  control  groups  had  normal  bronchi  and 
parenchyma and had no conspicuous cellular infiltrates (Fig. 
6C, D). When examined on 10
th day of prophylactic (day 36), 
t h e  i n f i l t r a t i o n  w a s  d r a s t i c a l l y  r e d u c e d  i n  P 1 - t r e a t e d  m i c e  
comparable  to  that  of  PBS-treated  control  mice  (Fig.  6E). 
P2-treated mice also exhibited decrease in lung tissue infiltra-Asp f1 Epitopes Protective Against Allergic Aspergillosis
Neelkamal Chaudhary, et al.
186 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 5 October 2009
Figure 5. Levels of IL-5 cytokine in mice splenic supernatants (A) and Lung EPO (Eosinophil Peroxidase) activity in lung homogenates (B) after
prophylactic and therapeutic treatment with PBS or Asp f1 peptides P1-P3. Data represents the mean±SD of triplicate determinations with five
mice per group, *p＜0.05 versus PBS-treated Afu challenged mice, 
†p＜0.05 versus PBS-treated ABPA mice.
tion when compared to PBS-treated Afu challenged mice (Fig. 
6F). No marked reduction in tissue infiltration was observed 
in P3-treated mice when compared to PBS-treated Afu-chal-
lenged mice (Fig. 6G). In therapeutic (day 42) regimen, the 
infiltration  was  markedly  reduced  in  P1  comparable  to 
PBS-treated  non-challenged  control  mice  (Fig.  6H).  P2  and 
P3-treated ABPA mice showed decrease in infiltration when 
compared  to  PBS  treated  ABPA  mice  (Fig.  6I,  J).
DISCUSSION
The results demonstrate that peptides derived from the im-
munodominant  N-terminal  region  of  Asp  f1,  a  major  aller-
gen/antigen of Afu, have immunomodulatory properties lead-
ing to predominant allergen-specific TH1 responses. Several 
studies  have  reported  immunodominant  T-cell  epitopes  de-
rived from house dust mite (Der p1), cat allergens (Fel d1), 
dog allergen (Can f1), and bee venom allergen (PLA-2) which 
inhibited allergen-specific TH2 responses by skewing the im-
mune  response  towards  TH1  (31,32,35-38).  Few  of  these 
studies  also  emphasized  that  administration  of  single  im-
munodominant peptide results in inhibition of responses to 
the  entire  allergen,  indicating  that  not  all  allergen-derived 
T-cell epitopes have to be present to inhibit allergic responses 
(32,36). In contrast to other IgE-mediated allergies, immuno-
therapeutic interventions against mold allergy have been chal-
lenging due to multiple allergenic components and difficulty 
in  standardization  of  fungal  extracts  (39-41).  Owing  to  the 
identification of major allergens/antigens of Afu and their im-
munodominant T-cell epitopes, safer peptide based-immuno-
therapy could be more promising approach against Afu -in-
duced  allergies  (16,19,26).
    Evaluation of Asp f1 peptides (P1-P3) in H2I
d BALB/c mice, 
high responders to Afu allergen, indicated capability of these 
peptides  in  redirecting  cytokine  profile  from  TH2  towards 
TH1 in both naïve and ABPA mice. Significant suppression 
and  decline  in  Afu-specific  IgE  levels  observed  in  prophy-
lactic (in P1-, P2- and P3-treated naïve mice) and therapeutic 
(in  P1-  and  P2-treated  ABPA  mice)  regimen,  respectively, 
were associated with increased IFN-γ/IL-4 ratios. Subsequent 
increase in IgG2a/IgG1 ratios observed in the similar groups 
of mice and suppressed Afu-specific IgG levels markedly in 
prophylactic (in P1-, P2- and P3-treated) regimen, indicated 
the shift from predominant TH2 to TH1 type. It has been re-
ported that in the murine system IFN-γ regulates the isotypes 
of antibodies secreted during both in vivo and in vitro humor-Asp f1 Epitopes Protective Against Allergic Aspergillosis
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Figure 6. Histopathological examination of the lung sections stained with hematoxylin and
eosin (H&E) and observed at 20×, from the groups of PBS or Peptide-treated mice in 
prophylactic and therapeutic regimen. (A) PBS-treated Afu-challenged mice (B) PBS-treated 
ABPA mice (C) PBS-treated non-challenged control mice (D) PBS-treated non-challenged 
control mice (E) P1-treated naïve mice (F) P2-treated naïve mice (G) P3-treated naïve mice
(H) P1-treated ABPA mice (I) P2-treated ABPA mice (J) P3-treated ABPA mice. Each micrograph
represents the observations in triplicate (a minimum of 10 fields) made with four lung 
specimens of five mice per group.
al  responses,  leading  to  the  stimulation  of  IgG2a  secretion 
and in the suppression of secretion of both IgG1 and IgE anti-
bodies (42). Kozutsumi  et al studied the effect of Japanese 
cedar pollinosis Cry-consensus peptide (CCP) on Cry j1-spe-
cific  TH1/TH2  responses  using  B10.S  as  a  mice  model. 
Corroborating with our results, CCP-treated (subcutaneously) 
mice exhibited increase in Cry j1- specific IgG2a antibodies, 
decreased IgG1 and IgE production, and increased secretion 
of IFN-γ cytokine by splenocytes (43). Similarly, treatment 
of PLA2 (a major bee venom allergen)-sensitized mice with 
intraperitoneal  injections  of  a  mixture  of  three  overlapping 
peptides  (44∼60  mer)  spanning  the  entire  PLA2  molecule 
(100 μg/peptide) induced a sharp drop in PLA2-specific IgE 
antibodies,  an  increase  in  specific  IgG2a  antibodies  with  T 
c e l l  c y t o k i n e  s e c r e t i o n  s h i f t i n g  f r o m  a  T H 2  t o  T H 1  p r o f i l e  
(44).  In  a  separate  study,  it  has  been  reported  that  pep-Asp f1 Epitopes Protective Against Allergic Aspergillosis
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tides-derived  from  PLA-2  were a b l e  t o  m o d u l a t e  a n  e s t a b -
lished TH2 response, indicated by decreased levels of PLA2- 
specific IgE and IgG1 antibodies, and declined IL-4/IFN-γ ra-
tio  (31).
    Successful immunotherapy has also been shown to be as-
sociated  with  reductions  in  numbers  of  eosinophils  at  sites 
of inflammation (45,46). The recruitment and differentiation 
of eosinophil progenitor cells in the bone marrow as well as 
the  infiltration  and  survival  of  eosinophils  at  sites  of  in-
flammation are all regulated by IL-5 (47). Significant reduc-
tion in levels of IL-5 correlated with the reduced eosinophil 
peroxidase  (EPO)  activity  in  mice  prophylactically  treated 
with peptides P1, P2 and P3, and therapeutically with P1. The 
administration of Der p1-derived immunodominant peptide to 
the  nasal  mucosa  of  mice  protected  against  airway  inflam-
mation with significant reductions in IL-5 levels and eosino-
phil infiltration into the airways following allergen challenge 
(32). However, a decrease in the levels of IL-5 cytokine did 
not result in protection against airway eosinophilia in P3 pep-
tide-treated mice in prophylaxis, suggesting other factors con-
tribute  to  the  reduction  in  eosinophil  numbers  as  reported 
earlier (48). It was interesting to note that in therapeutic regi-
men  P2  peptide  induced  the  decrease  in  IgE  antibodies, 
showed higher ratios of IgG2a/IgG1 antibodies and IFN-γ/ 
IL-4 cytokines than peptides P1 and P3. However, only P1 
treated mice showed reduction in EPO activity, IL-5 and in-
flammatory cells infiltration in lung histological sections com-
parable to non-challenged  control. Recently,  it is becoming 
clear  that  immunopathogenesis  of  fungal  infections  cannot 
solely be explained in terms  of  TH1/TH2  balance,  and  the 
important role of TH17 pathway in fungal infections has been 
reported  (49).  Importantly,  functional  antagonism  between 
TH17 and T reg has also been described (50). Thus, discrep-
ancy  observed  between  peptide-induced  TH1/TH2  cytokine 
profile and resolution of lung inflammation in the present da-
ta suggest that other pathways (possibly TH17or Treg) could 
play significant role in Afu-induced allergies and need to be 
investigated.
  It is important to mention that in previous studies peptide 
P1 induced in vitro histamine release from Afu-sensitized ba-
sophils  of  ABPA  patients  higher  than  peptides  P2-P5,  al-
though significantly less than the 3wcf (19). Therefore, mech-
anism of protection and induction of TH1 cytokines by pep-
tide  P1  both  prophylactically  and  therapeutically  in  in  vivo 
conditions is difficult to explain and requires further studies. 
Akdis and colleagues have reported in their studies that hista-
mine enhances secretion of IFN-γ by allergen-specific TH1 
cells,  whereas  TH2  cytokines  (IL-4,  IL-13)  were  inhibited 
(51,52). Likewise, a recent study by Johansen  et al demon-
strated that antihistamine-treated CBA mice exhibit increased 
sensitization  against  bee-venom  allergen  extracts  leading  to 
increased levels of IgE antibodies while decreasing the secre-
tion  IgG2a  antibodies  (53).  Further,  redirection  of  the  im-
mune  response  towards  TH1  has  been  demonstrated  using 
whole-allergen  (with  histamine  release  potential)  immuno-
therapy  for  several  IgE-mediated  allergies  (54).
    Since  pulmonary  eosinophilia  was  not  inhibited  by  the 
peptides P2 and P3 in the therapeutic regimen and P3 in pro-
phylactic regimen, it is likely that these peptides may not be 
effective for immunotherapy in the amounts administered and 
doses or routes of the peptide have to be optimized for the 
therapeutic  or  prophylactic  potential.
    Taken together, increased production of protective TH1 an-
tibodies, elevated levels of TH1 cytokines and suppression of 
lung eosinophilia induced by Asp f1 peptides P1 and P2 pro-
phylactically,  and  P1  therapeutically,  establishes  the  useful-
ness  of  these  peptides  in  the  exploration  of  peptide-based 
protection against Afu-induced allergies. After establishing the 
protective efficacy of Asp f1 peptides in mice, we evaluated 
whether  these  results  could  be  extrapolated  to  humans  by 
predicting affinity of the peptides with various MHC class II 
molecules. 
    Peptides  P1-P5  were  predicted  to  be  promiscuous  in  the 
present study as shown by their binding (medium binding af-
finity) to HLA-DR alleles such as HLA-DR2, HLA-DR4, HLA- 
DR5, HLA-DR7, and also with preponderant alleles such as 
HLADRB1*1501  (DR2)  and  HLADRB1*0401  (DR4)  following 
SVM  method.  In  Asian-Indian  population  HLADRB1*1501 
while  in  Caucasian  population  both  HLADRB1*1501  and 
HLADRB1*0401  cover  ∼60%  of  HLADRB1  allele  frequency 
(55,56).  Texier  et  al  have  identified  T-cell  epitopic  regions 
from the major bee venom allergen, Phospholipase A-2, that 
efficiently bind to the predominant HLA-DRB1 molecules of 
Caucasian populations, suggesting as potential candidates for 
immunotherapy to bee-venom allergy (56). HLA association 
studies  have  revealed  that  the  predisposition  to  develop 
ABPA is associated with HLA-DR2 and DR5, and possibly DR4 
or DR7 (15). Therefore, predicted higher affinity of peptide 
epitope P1 than other peptides with HLA-DR5 suggests that 
this peptide may represent as a promising candidate for pep-
tide-based intervention against allergic aspergillosis. However, 
e x p e r i m e n t a l  s t u d i e s  a r e  r e q u i r e d  t o  c o n f i r m  t h e  p r e d i c t e d  Asp f1 Epitopes Protective Against Allergic Aspergillosis
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binding  affinities  to  these  HLA-alleles.
    To conclude, our data suggests that P1, showing TH1 re-
sponse  in  both  prophylactic  and  therapeutic  regimens  in 
Balb/c  mice  challenged  with  Afu-allergens/antigens,  is  the 
most promising candidate and may be explored for the devel-
opment of peptide-based immuno-therapeutics of allergic as-
pergillosis  in  humans.
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